The European Medicines Agency is holding a press conference to discuss the relationship between the AstraZeneca vaccine and blood clot formation.
EMA’s conclusions are particularly important for Croatia, because our country has ordered the most vaccines from AstraZeneca.
“After investigating dozens of blood clots after the EU vaccination against AstraZenec, the EMA Safety Committee concluded that the benefits of AstraZeneca outweigh the risk of side effects. Covid-19 is a very serious disease that causes hundreds of blood clots in Europe every day. People have lost their lives. European Union: EMA Director Emer Cooke said: “This vaccine has proven to be very effective and can prevent hospitalization and serious illness. This vaccine can save lives and is extremely important in the fight against COVID-19. “
EMA investigated 86 reported cases of clot formation. Approximately 20 million people in the European Union have been vaccinated with the AstraZenecom vaccine.
Cook said: “We came to the conclusion that the combination of abnormal blood clots and low platelets should be listed as possible rare side effects of the vaccine.”
“When millions of people receive the vaccine, very rare side effects may occur, which have not been observed in clinical trials. This shows that our surveillance system is working. These very rare events have been identified. A country’s Any decision should take this into account. Explain the pandemic situation in each country.” “Cook said.
According to reports, within two weeks of vaccination, most reported cases of blood clots occurred in women under 60 years of age.
Said at the press conference: “Our investigation concluded that blood clots are a very rare side effect of the AstraZeneca vaccine.”
“Most cases are reported in women under the age of 60, but based on current evidence, no specific risk factors have been identified, such as age, sex, or previous medical conditions for thrombosis. Blood coagulation was reported in all groups. AstraZeneca will Other studies are needed to investigate the occurrence of blood clots,” EMA said.
EMA reports that one possible explanation for the combination of blood clot formation and low platelet counts is that “the body’s immune system reacts to conditions similar to those in patients receiving heparin (heparin-induced thrombocytopenia or HIT). Kind of situation.”
EMA investigates reports of brain clots in rare cases called cerebral venous sinus thrombosis (CVST). In the European Economic Community composed of the European Union, Iceland, Liechtenstein and Norway, AstraZenecom has vaccinated 9.2 million people.
In the United Kingdom, 30 cases have been confirmed, including 3 deaths, and 18.1 million people have been vaccinated as of March 24.
After the EMA announcement, EU health ministers will meet on Wednesday.